The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy

British Journal of Dermatology

Volumn 149, Issue 1, 2003, Pages 124-130

  Choudry, K ^a   Brooke, R C C ^a   Farrar, W ^b   Rhodes, L E ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

5 aminolaevulinic acid; Iron chelation; Nonmelanoma skin cancer; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT; PROTOPORPHYRIN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREAM; DESENSITIZATION; DOSE RESPONSE; ERYTHEMA; FEMALE; FLUORESCENCE; FOREARM; HUMAN; HUMAN EXPERIMENT; IONTOPHORESIS; IRON CHELATION; MALE; NORMAL HUMAN; PHOTODERMATOSIS; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RED LIGHT; SKIN CARCINOMA; SUPERFICIAL CANCER;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERYTHEMA; FEMALE; FLUORESCENCE; HUMANS; IONTOPHORESIS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; SKIN NEOPLASMS;

EID: 0041633674     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05351.x     Document Type: Article

References (21)

1. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552-67.
2. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990; 6: 143-8.
3. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. J Am Acad Dermatol 1993; 28: 17-21.
4. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-57.
5. Ortel B, Tanew A, Hönigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cell-modification by desferrioxamine. J Photochem Photobiol B Biol 1993; 17: 273-8.
6. Berg K, Anholt H, Bech Ø, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer 1996; 74: 688-97.
7. Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995; 133: 282-8.
8. Rhodes LE, Tsoukas MM, Anderson RR, Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermatol 1997; 108: 87-91.
9. Tan WC, Krasner N, O'Tool P, Lombard M. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron. Gut 1998; 42: 759-60.
10. Ryan TP, Aust SD. The role of iron in oxygen mediated toxicities. Crit Rev Toxicol 1992; 22: 119-41.
11. Lin F, Girotti AW. Photodynamic action of Merocyanine 540 on leukaemia cells: iron-stimulated lipid peroxidation and cell killing. Arch Biochem Biophys 1993; 300: 714-23.
12. Lin F, Bertling CJ, Geiger PG, Girotti AW. Delayed hyperresistance of endothelial cells to photodynamic inactivation after contact with hemin. Photochem Photobiol 1998; 68: 211-17.
13. Pourzand C, Reelfs O, Kvam E, Tyrrell RM. The iron regulatory protein can determine the effectiveness of 5-aminolevulinic acid in inducing protoporphyrin IX in human primary skin fibroblasts. J Invest Dermatol 1999; 112: 419-25.
14. Jacobs JM, Sinclair PR, Sinclair JF et al. Formation of zinc protoporphyrin in cultured hepatocytes: effects of ferrochelatase inhibition, iron chelation or lead. Toxicology 1998; 125: 95-105.
15. Nunn AV, Norris WP, Hawk JLM, Cox TM. Zinc chelatase in human lymphocytes: detection of the enzymatic defect in erythropoietic protoporphyria. Anal Biochem 1988; 174: 146-50.
16. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62: 906-13.
17. Harth Y, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumours, utilising aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol Surg 1998; 24: 723-6.
18. Malik Z, Kostenich G, Roitman L et al. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B Biol 1995; 28: 213-18.
19. De Rosa FS, Marchetti JM, Thomazini JA et al. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolaevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000; 65: 359-66.
20. Curnow A, McIllroy BW, Postle-Hacon MJ et al. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br J Cancer 1998; 78: 1278-82.
21. Bech Ø, Phillips D, Moan J, MacRobert AJ. A hydroxpyridinone (CP94) enhances protoporphyrin IX formation in 5-aminolaevulinic acid treated cells. J Photochem Photobiol B Biol 1997; 41: 136-44.